1. Home
  2. IMNM vs BUSE Comparison

IMNM vs BUSE Comparison

Compare IMNM & BUSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$18.07

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Logo First Busey Corporation

BUSE

First Busey Corporation

HOLD

Current Price

$28.26

Market Cap

2.3B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMNM
BUSE
Founded
2006
1868
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Major Banks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.6B
2.3B
IPO Year
2020
1996

Fundamental Metrics

Financial Performance
Metric
IMNM
BUSE
Price
$18.07
$28.26
Analyst Decision
Strong Buy
Buy
Analyst Count
10
6
Target Price
$32.80
$27.17
AVG Volume (30 Days)
1.2M
678.5K
Earning Date
05-08-2026
04-28-2026
Dividend Yield
N/A
4.04%
EPS Growth
51.40
N/A
EPS
N/A
0.52
Revenue
$6,941,000.00
$719,584,000.00
Revenue This Year
N/A
$23.84
Revenue Next Year
$1,127.34
$3.82
P/E Ratio
N/A
$55.36
Revenue Growth
N/A
55.66
52 Week Low
$7.96
$21.63
52 Week High
$27.65
$28.90

Technical Indicators

Market Signals
Indicator
IMNM
BUSE
Relative Strength Index (RSI) 33.00 63.24
Support Level $16.81 $25.69
Resistance Level $19.16 N/A
Average True Range (ATR) 0.92 0.55
MACD -0.21 0.11
Stochastic Oscillator 1.24 70.43

Price Performance

Historical Comparison
IMNM
BUSE

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

About BUSE First Busey Corporation

First Busey Corporation is a financial holding company whose subsidiaries provide retail and commercial banking services, remittance processing, and offer financial products and services with banking centers in Illinois, Missouri, Florida, and Indiana. The company's operations are managed through three operating segments consisting of Banking, FirsTech, and Wealth Management. The banking segment generates a vast majority of its revenue.

Share on Social Networks: